Category: Health

First Lady Melania Trump, President Donald Trump, FIFA President Gianni Infantino and his wife Leena Al Ashqar take part in the FIFA Club World Cup 2025 Final Football Match between England's Chelsea and France Paris Saint-Germain in Metlife Stadium in East Rutherford, July 13, 2025.

Charly Triballeau | AFP | Getty pictures

President Donald Trump underwent a comprehensive medical examination that showed that he has a common vein disorder but freed him from more serious diseases, the White House announced on Thursday.

The White House revealed the medical information of the 79-year-old president in response to speculation after photos showed Trump with swollen ankles.

The press spokeswoman Karoline Leavitt said that Trump had noticed the swelling in the past few weeks and received a thorough assessment from the medical unity of the White House.

He was diagnosed with chronic venous insufficiency, which Leavitt described as “benign and common illness, especially in people over 70 years”.

Chronic venous insufficiency occurs when the leg veins of a person are damaged, which means that according to Cleveland Clinic, limits circulation and grab blood in the legs.

The chronic venous insufficiency affects about 1 out of 20 adults, and the risk increases with age, according to the clinic.

Leavitt said Trump had no pain before the disease.

A bruise is visible to President Donald Trump's right hand, which seemed to be covered with make -up when Trump was waiting to welcome the Crown Prince Salman Bin Hamad Al Khalifa from Bahrain when he arrived in front of the west wing of the White House on July 16, 2025.

Mehmet Esser | AFP | Getty pictures

Leavitt also dealt with bruises on the hand of Trump. She said that they were caused by irritation by “frequent shake”, paired with his aspirin regime.

The medical examination showed no evidence of deep venous thrombosis or an arterial disease, said Leavitt.

Trump's blood underground results were all “normal limits”, and an echocardiogram confirmed “normal heart structure and function” without “signs of heart failure, kidney impairment or systemic illness,” she added.

Leavitt said in briefing on Thursday that bruises such as what was seen in Trump's hands, is a common side effect of regular use of aspirin, which Trump takes as part of a “standard cardiovascular prevention program”.

“The president is still with excellent health, of which I think they all testify every day,” she said.

The doctor of the White House, Sean Barbabella, wrote in an April memo that Trump “remains in excellent physical health” and is “fully fit” to perform the tasks of the presidency.

Read the Barbabella on Thursday on Thursday on Thursday.

Zoom in Iconarrows that show outwards

President Donald Trump's state of health.

With kind permission: The White House

This is the development of news. Please check for updates.

Cr | IStock | Getty pictures

A version of this article was first published in CNBCS Healthy Return's newsletter, in which the latest health news leads directly to their inbox. Subscribe here to get future expenses.

Another potential competitor for blockbuster fat -lane treatments of Eli Lilly And Novo Nordisk Only positive data shown – but this time it comes from China.

In a study in the late stage in China, an experimental weekly injection developed by the Chinese pharmaceutical manufacturer Hengrui Pharma and his partner Kaailera therapeutics based in the USA brought the drug manufacturers onto the route to take consent there.

Kailera belongs to several companies such as Merck, Novo Nordisk and Regeneron, who have won the Chinese market in search of a medication that could win a piece of the booming market for weight loss medicines. In May 2024, Kaailera licensed the rights outside of the Greater China region for several experimental medication from Hengrui in return for more than $ 100 million in advance payments and short-term payments, a share share of 20% and almost $ 6 billion in future milestones.

As the medication, which was designated in the study with the HRS9531, was carried out in the study: After 48 weeks, it helped the patient to lose almost 18% of their body weight, which is more than 16% higher than those on a placebo saw.

Almost 9 out of 10 people who received the injection lost at least 5% of their body weight, and 44.4% of the patients achieved at least 20% weight loss, according to companies. After 48 weeks there was no plateau.

The companies did not open any specific safety data or how well the patients tolerated the medication, and only said that these results match previous data for treatment and other GLP-1. Most undesirable events from the injection were gastrointestinal -related and light to moderate heaviness, the companies said.

Hengrui will submit an application for admission for the medication in China. In the meantime, Kailera will start global studies that use higher doses and keep patients in treatment for longer, said Ron Renaud, CEO of the startup, in the publication.

It will probably still take a few years before HRS9531 comes into the market, especially in the USA and other nations outside China. However, the results of the drug seem to be promising and, as a potential competitor to position Eli Lilly's weekly weight loss, zepbound.

Both drugs work by activating two naturally produced hormones in the body: glucagon-like peptide-1, known as GLP-1 and glucose-dependent insulinotropic polypeptide or gip. The combination is intended to slow down the emptying of the stomach, feel people full longer and suppress appetite by slowing down hunger signals in the brain.

In two phase, three studies that enroll about 3,000 adults with obesity or type -2 -diabetes, Zepbound helped the patient to lose an average of up to 21% of their body weight for over 72 weeks.

It is difficult to compare the results of various clinical studies directly, especially since the latest results on HRS9531 only came from more than 500 patients. However, the drug still reached significant weight loss for over 48 weeks and increased the hopes of its potential over a longer period of time.

In the meantime, the weekly injection of Novo Nordisk only aims at GLP-1.

Feel free to send Annikakim.constantino@nbcuni.com tips, suggestions, ideas and data to Annika.

Latest in the healthcare system Tech: 23Andme co-founder Wojcicki's non-profit organization acquires genetic test company

Anne Wojcicki, co -founder and Chief Executive Officer from 23Andme Inc., during the South by Southwest (SXSW) Festival in Austin, Texas, USA, on Friday, March 10, 2023.

Jordan Vonderhaar | Bloomberg | Getty pictures

Well, guys, after a long saga, Anne Wojcicki has officially regained control of the competitive gene tests 23Andme.

Wojcicki was a co -founder of 23Andme and served as CEO until the company applied for insolvency protection in Chapter 11 in March. Your new non -profit TTAM Research Institute has completed the acquisition of the business preparations for personal genome service and research services from 23Andme, the company said on Monday.

“As part of TTAM, 23Andme continues to work and offers customers personalized DNA test and research services,” said the company in a press release. “TTAM is committed to supplying customers from elections and transparency with their data, including the opportunity to change their decision on whether they should take part in research.”

According to Wall Street Journal, TTAM is an abbreviation for the first letters from 23Andme.

23Andme shot with DNA test kits at home in the mainstream, which gave the customer an insight into their family history and genetic profiles. However, the five-time CNBC Disruptor 50-company had trouble getting recurring income and lifelong research and therapeutic agencies increased to the public.

When it became clear that 23andmes finance data was shaky, Wojcicki submitted several suggestions to take the company privately while she was still his managing director. These plans were unsuccessful and ultimately had to compete against other potential buyers in an insolvency auction.

And of course there were some unexpected twists.

In May, Regeneron announced Pharmaceuticals to acquire most assets of 23 and 23Ande for 256 million US dollars after it is ahead during insolvency auction. But Wojcicki submitted a separate offer of 305 million US dollars via TTAM and urged to reopen the auction.

A month later she did exactly that and TTAM announced that it successfully overrunned Regeneron.

“I am thrilled that the TTAM research institute can continue the 23Andme mission to help people access, understand and benefit from human genome,” said Wojcicki in June.

Feel free to send tips, suggestions, story ideas and data to Ashley at Ashley.capoot@nbcuni.com.

The logo for the Food and Drug Administration is before a press conference to remove synthetic dyes from American food supply on April 22, 2025 in Washington, DC, in the Health and Human Services headquarters in Washington.

Nathan Posner | Anadolu | Getty pictures

The US Food and Drug Administration published a warning letter on Tuesday that was aimed at the Wearable Company Whoop at the wrist lawyer and claims that it is a new blood pressure function without proper approvals.

The letter is about whoops Blood printing Insights (BPI) feature, which the company introduced in addition to its latest hardware start in May.

According to the WHOOP, its BPI function uses blood pressure information to offer performance and wellness knowledge that provides consumers and improve sporting performance.

However, the FDA said on Tuesday that the BPI function of whoop is intended to diagnose, heal, treat or prevent diseases – an important distinction that would re -classify the wellness tracker as a “medical device”, which must undergo strict test and approval process.

“The blood pressure estimate is not a low -risk function,” said the FDA in the letter. “A faulty low or high blood pressure reading can have significant consequences for the user.”

A Whoop spokesman said that the company's system only offers a single daily estimated area and a center that distinguishes it from medical blood pressure devices that are used to diagnose or treat high blood pressure.

According to the company, Whoop users who buy the “Whoop Life” subscription level in the amount of $ 359 can use the BPI function to get daily insights into blood pressure, including an estimated systolic and diastolic areas.

Whoop also demands that users record three conventional cuff readings in order to act as a baseline to unlock the BPI function.

In addition, the spokesman said that the BPI data is no different from other wellness metrics with which the company has to do. As the variability of the heart rate and the respiratory rate can have medical purposes, according to the speaker, they are also permitted in a wellness context.

“In this case, we believe that the agency exceeds its authority by trying to regulate a non-medical wellness function as a medical device,” said the whoop spokesman.

According to Dr. Ian Kronish, an internist and co-director of the Hypertension Center at Columbia University, is high blood pressure, also called high blood pressure, the top risk factor for heart attacks, strokes and other types of cardiovascular diseases.

Kronish told CNBC that Wearables such as Whoop are a big up -and -coming topic among high blood pressure experts, also because there are “concerns that these devices are not yet proven to be correct”.

If patients do not receive precise blood pressure values, they cannot make well -founded decisions about the care they need.

At the same time, Wearables such as Whoop presented a “big chance” for the patients to take more control over their health and that many specialists are enthusiastic about working with these tools.

Understandably, it can be confusing for consumers to navigate. Kronish encouraged the patients to talk to their doctor about how they should use wearables like Whoop.

“It is really great to hear that the FDA helps more to inform consumers,” said Kronish.

FileToto: The headquarters of the US Food and Drug Administration (FDA) can be seen in Silver Spring, Maryland, November 4, 2009.

Jason Reed | Reuters

Whoop is not the only portable manufacturer that researches blood pressure monitoring.

Omron and Garmin Both offer medical blood pressure monitoring with on-demand measurement values that fall under the FDA regulation. Samsung also offers blood pressure leading technology, but is not available on the US market.

Apple Also annoyed a blood pressure sensor for his watches, but could not deliver. In 2024 the Tech -Riese received the FDA permission for the detection of sleep apnea.

Whoop previously received an FDA Clearance for its ECG function, with which the electrical activity of a heart is recorded and analyzed in order to recognize potential irregularities in the rhythm. But when it comes to blood pressure, Whoop believes that the perspective of the FDA is out of date.

“We do not believe that blood pressure is more or less sensitive than other physiological metrics such as heart rate and respiratory frequency,” said a spokesman. “It seems that the concerns of the FDA can have outdated assumptions about the blood pressure, which is only a clinical domain and is inherently associated with a medical diagnosis.”

The FDA said who could be subjected to the WHOOP regulatory measures such as confiscation, injunction and civil allowance sentences if it is not tackled the violations that the agency identified in its letter.

Whoop has 15 working days to react with steps that the company has undertaken to remedy the violations and how it will prevent similar problems.

“Even BPI's disclaimers do not change this conclusion, since they are not sufficient to outweigh the fact that the product should provide a blood pressure estimate through design that is inherently associated with the diagnosis of a disease or a state,” said the FDA.

REGARD: See CNBC's full interview with the FDA Commissioner Dr. Marty Makary

The Food and Drug Administration will take into account the affordability of drugs if it grants companies new vouchers that accelerate the approval of some treatments, the Commissioner of the agency Marty Makary told CNBC on Friday.

In June, the FDA announced a national priority voucher plan that aims to reduce the time to check drugs to one to two months for companies that they say, which they say, support “US national interests”. In previous announcements on the voucher program, however, it was not expressly mentioned that drugs became more affordable as a criterion.

“We enter the affordability of drugs as a national priority,” Makary told CNBC.

The reduction in drug prices is an important goal of the Trump administration, which is exposed to a difficult total amount, since it threatens to raise up to 200% tariffs for pharmaceuticals imported in the USA in order to form the production of medicinal products.

The commissioner of the Food and Drugs Administration, Marty Makary, speaks at a press conference on the removal of synthetic dyes from American food supply on April 22, 2025 in Washington, DC.

Nathan Posner | Anadolu | Getty pictures

Makary added that President Donald Trump is “very relentless that he would lower drug prices for Americans, and he does not like the Americans in the United States to be torn down with two or five or ten times.

However, it is unclear how the Trump management takes affordable when checking a drug

On the FDA website, four examples of “national priorities” are currently being described, with which it is determined which companies receive a voucher as part of the new program. This includes combating a health crisis in the United States, providing “more innovative healing” for Americans, fighting public health and increasing domestic purposes as a national security problem “.

According to a report by the Wall Street Journal in June, a medicine may already have been affected.

A spokesman for the Department of Health and Human Services confirmed that the FDA will consider the affordability of the drugs for the program and that the criteria are not limited to previous examples.

When Makary was asked that it was examples of a health crisis that companies can affect with their medication, he would like to see a remedy for type -1 diabetes, more treatments for neurodegenerative diseases and a universal flu so that we do not have to try to guess which tribe comes. ”

He also said that he wanted to see more treatments for cancer in stage 4 or if the disease spreads from its original location to distant parts of the body.

“We have a committee that is set up, which determines which products and companies receive these vouchers as part of a pilot,” said Makary. “But we have to try new things. We have to ask ourselves why it takes so long to come to the market? And we want to see more remedies and sensible treatments for Americans.”

The FDA will issue new vouchers this year. After a one -year pilot phase, the agency can increase the number of fast permits that companies grant.

Some Wall Street analysts have previously announced that the voucher program could be more effective than tariffs to encourage drug manufacturers to bring their production to the USA

However, there are questions about the risks of accelerating drug reviews to 30 days, which the fastest of the FDA has ever carried out.

Another potential concern is whether the FDA will offer political allies of the Trump administration vouchers that could include companies that would normally examine the agency's employees.

US President Donald Trump presents a comprehensive expenditure and tax legislation, which is known as “a great beautiful act of law” after signing it in the White House in Washington, DC, USA on July 4, 2025.

Leah Millis | Reuters

A version of this article was first published in CNBCS Healthy Return's newsletter, in which the latest health news leads directly to their inbox. Subscribe here to get future expenses.

We are back with President Donald from the holiday weekend Trump's “big beautiful” bill officially signed into the law.

His pioneering tax cuts and its spending package include more than 1 trillion dollar cuts in Medicaid, which endangers millions of Americans in need of protection without health insurance and hospitals and centers that are provided to them. While reducing health expenditure has massive human costs, you will also influence the pharmaceutical industry.

Medicaid only makes up part of the income of many drug manufacturers in the USA – and an even lower proportion of their overall revenue worldwide. Medicaid also refunds companies for drugs at lower prices than in other programs such as Medicare or Commercial Insurance, as can be seen from a Monday notice of the Leer Link Partner David Risinger's analyz.

This is mainly due to a program in which medication manufacturers provide discounts in Medicaid for the insurance of their medicinal products, which leads to lower net drug prices.

Nevertheless, Risinger said that “future loss of income was a marginal negative” for drug manufacturers.

He also said that some corporate sales are exposed to the Medicaid market more than others, based on earlier corporate comments and the internal estimates of his company.

Spot point pharmaceuticals And Gilead You rely more on Medicaid than on other companies with a large cap, said Risinger. According to the note, Medicaid makes 25% of the US turnover of Vertex and 22% of the domestic sales of Gilead.

At a conference in June, Vertex announced that Medicaid is 23% of the turnover from his cystic fibrosis medication, which are the most important sales drivers of the company. The track: half of all children and a third of all adults with this genetic state rely on Medicaid to afford the treatments and the care they need to live a healthy life, according to the cystic fibrosis foundation.

The Gilead headquarters in Foster City, California, USA, on Monday, January 29, 2024.

David Paul Morris | Bloomberg | Getty pictures

Medicaid also plays a major role in the HIV prevention and treatment, especially in underserved populations, which is a central focus for Gilead. For example, the biktarvy of the company's HIV treatment pill in relation to the entire Medicaid drug expenditure in 2022 was equipped as the second highest drug medication and, according to a note of Jefferies analysts, was still one of the most frequently used drugs in the program in March.

Nevertheless, the analysts said that Hit Gilead's business would probably be “manageable” by Medicaid. The note was based on estimates from an earlier version of the invoice.

Trade insurers also offer most of the cover for HIV prevention and ongoing treatment, while Medicaid plays a smaller one Important, role.

Medicaid represents 12% of Johnson & JohnsonDomestic sales (without the business with a medical device) and 12% of 12% Novo NordiskThe US income. Under large pharmaceutical companies, Bristol Myers Squibb And Pfizer Had the lowest exposure, with only 4% of their US revenue comes from Medicaid.

Risinger said Medicaid makes 15% of RocheThe US income. In a statement on Tuesday, however, Roche said that the market is only less than 10% of the sales in the country.

Risinger found that significant Medicaid cuts will only occur after the intermediate elections in November 2026, so that the financial effects on drug manufacturers will start essentially in 2027.

There is also another important victory for drug makers in Trump's legislative template: a provision that is freed more medicines from the Medicare drug price negotiations of inflation reduction act.

We will continue to monitor the effects of legislation on the industry, so stay tuned.

Feel free to send Annikakim.constantino@nbcuni.com tips, suggestions, ideas and data to Annika.

Latest in the healthcare system Tech: AI startups have drawn most of the digital health financing this year this year

We are halfway by 2025, which means that we have some checking financing data for digital health. Even in a volatile macroeconomic and political environment, the sector saw “strong dynamics” according to a new report by Rock Health.

Digital Health companies in the United States received $ 6.4 billion in funds in the first half of the year, compared to $ 6 billion in the previous year and 6.2 billion US dollars in the first half of 2023, according to the report. The sector increased 3.4 billion US dollars in venture in the second quarter alone, which has increased an average of $ 2.6 billion per quarter since 2023.

Start-ups that use artificial intelligence as the core component of their product increased 62% of all digital health regulations in the first half of the year when AI-capable companies have recorded a large part of the new capital. These companies pulled an average of 34.4 million US dollars per round.

“Digital health proves that it is more than just steady and resistant. The sector enters into a new phase of traction and effect, with AI playing a linchpin,” said Rock Health.

But while the financing has expired, the deal Count has dropped slightly. Digital Health Companies completed 245 deals in the first year of the year, while in the same period of the previous year 273, the report says. Nevertheless, megadeals or increases over 100 million US dollars rise. In the first half of the year there were 11 megadeable, which fits the 17 megadedale at speed, which took place in all entire 2024.

This year there was also a flood of M&A activities within digital health. The sector closed in the first half of 2025 107 M&A agreements, which could quickly exceed the 121 M&A offers that were closed in 2024.

And much to facilitate many digital health investors, Hingse Health and Omada Health won the jump and debuted in public markets. Rock Health said these outputs are undeniable “the previous moments of outbreak from 2025”.

“These debuts for public market gave investors to the urgently needed redemption after a drought, hard public market services and a number of youngest take-off private individuals,” said Rock Health.

Read the full report here.

Feel free to send tips, suggestions, story ideas and data to Ashley at Ashley.capoot@nbcuni.com.

Hims & Hers Health Announced on Wednesday, it will be generic semaglutid in Canada as offer Novo NordiskThe patent about the marksmiths that Ozempic and Wegovy are supposed to run in January.

“Canada is a great opportunity to show what an affordable and high -quality weight loss care can look like,” said Andrew Dudum, co -founder and CEO of HIMS & HULS, in a press release. “Since the generic semaglutid is available worldwide for the first time, we focus on making it really accessible by combining the affordability with trustworthy, personalized care on a scale.”

HIMS, a telemedicine platform, is followed by a growing list of drug manufacturers that are redeemed on the past Patent of Novo Nordisk on his GLP-1. It is the first time that the company works in Canada.

Generics are essentially copies of a brand medication such as Ozempic or Wegven that deliver the same effectiveness, follow the same safety standards and are permitted after a patent. These drugs differ from composite versions of medication that are personalized treatments that are changed in the form or are provided in the form of doses available in different doses.

The Canadian Semaglutide market in 2024 generated sales of $ 1.18 billion and, according to the market research company Grand View Research, will probably achieve $ 4.03 billion by 2035.

There is still no generic version of Semaglutid on the market that was approved by the Canadian health authority, but the approval process has started for some in the industry.

Sandoz, a worldwide leading provider of generic medicine, informed science in early June that she submitted a generic version of Semaglutide with the Canadian regulatory authority Health Canada. HIMS did not say in his announcement that if he started a similar application for review, however, it found that it was working with “an approved partner” to ensure that all local laws and regulations follow.

More CNBC health insurance

Some in the industry have expressed concerns that Novo leaves its patent losses and it comes how Wegovy has lost the ground Eli Lilly“Zepbound, in the USA, but a spokesman for the company said CNBC that all decisions for intellectual property are” carefully taken into account “, and that” Time periods of exclusivity for pharmaceutical products can be available as part of their normal life cycle and generic treatments over time “.

This announcement of HIMS follows the closure of the recent takeover of the European Telegealth platform Zava by the company that extends the health platform in Europe to Ireland, France and Germany.

This also happens after Nordisk ended his cooperation with Hims & Husen, and cited concerns about the sales and promotion of cheaper failures of the company in weight loss medication.

How Novo lost his Canadian patent

According to documents submitted to the Canadian patent database, Novo kept a patent for Semaglutid, but the last time the company paid the annual maintenance fee in 2018.

The lawyers from Novo Nordisk requested a refund for the paid maintenance fee of $ 250 in Canadian dollars ($ 185) because the company had more time to check whether it wanted to pay them, according to the letters contained in the documents.

Two years later, the office sent a letter in which the fee in which a late fee now contained the total amount received to $ 450 did not enter into after the prescribed due date.

Novo Nordisk had to pay a one -year grace, but never, and so his patent in Canada has fallen for falling. It ended in 2020 when the fee had not been received, but it only expired in January.

The Canadian authorities confirmed in their correspondence: “As soon as a patent has expired, it cannot be revived”.

“To make affordable, holistic obesity treatment accessible has the potential to strengthen the local health system and to act the potential for millions of Canadians, to live a healthier and more fulfilling life,” said David Meinertz, General Manager of the International company at HIMS & HOR.

Do not miss these findings from CNBC Pro

US President Donald Trump during a cabinet seat in the White House in Washington, DC, USA, on Tuesday, July 8, 2025.

Aaron Schwartz | Bloomberg | Getty pictures

On Tuesday, President Donald Trump threatened to impose up to 200% tariffs on pharmaceuticals that were “very soon” imported into the USA.

“You will z.

But he suggested that these taxes would not come into force immediately, and said that he would give people “about a year and a half, half years”.

“We will give you a certain time to put together your action”

Details on pharmaceutical tariffs “will take place at the end of the month,” said Minister of Commerce Howard Lutnick after the cabinet seats to CNBC.

“With pharmaceuticals and semiconductors, these studies will be completed at the end of the month, and so the president will then determine his guidelines, and I will let him wait to decide how to do it,” said Lutnick.

The president repeatedly threatened and then changed the course for tariff proposals, so there is no guarantee that he will use pharmaceutical tariffs to 200%. According to Trump's comments, the pharmaceutical stocks were largely unchanged.

In a note on Tuesday, the analyst of Leerink Partners said David Risinger said that he was positive for the announcement for the industry, “because the tariffs are not implemented immediately … and it is unclear whether the administration will go through in the future.”

It has been Trump's most important comment on pharmaceutically specific tariffs since April when his administration initiated a so -called examination of section 232 for these products. This legal authority allows the trade knowledge to examine the effects of imports on national security.

These planned tariffs would affect the pharmaceutical company a long -awaited blow, many of which have pushed back, and warned that the taxes increase the costs, deter investments in the USA and disturb the pension chain of medicinal products that endanger the patients. The industry is already navigating through Trump's drug price guidelines that claim drug manufacturers both their profit size and their ability to invest in research and development.

Trump stated Eli LillyPresent Johnson & JohnsonPresent Abbvie And others are already putting more money into the USA after the production of domestic medications has shrunk dramatically in recent decades.

Phrma, the largest lobby group in the United States, repeated an earlier explanation that pushes back the pharmaceutical tariffs.

“Every dollar spent on tariffs is a dollar that cannot be invested in the American production or development of future treatments and remedies for patients,” said Alex Schriver, Senior Vice President of Public Affairs at Phrma.

“The industry shares the goal of President Trump to revitalize American production and recently announced hundreds of billions of dollars of US investments, but to place the tariffs for medicines for these efforts,” he continued. “Medicines were historically freed from tariffs because they can increase the costs and lead to bottlenecks.”

Cases of Kool-Aid-Jammers were stacked on April 27, 2025 in San Diego, California.

Kevin Carter | Getty pictures

Kraft Heinz Said on Tuesday that it will remove FD & C artistic dyes from its products by the end of 2027 and will not launch new products in the USA with these ingredients.

The company said in a publication that around 10% of the US articles use FD & C colors, the synthetic additives that make many food more visually appealing. Kraft Heinz brands that sell products with these dyes include, according to a power-Heinz spokesman for Kraft Heinz Crystal Light, Kool-Aid, Mio, Jell-O and Jet-Puffed.

The company removed artificial colors, preservatives and flavors of Kraft Makaroni and Cheese in 2016. According to Pedro Navio, President of North America at Kraft Heinz, Heinz Ketchup has never used artificial dyes. It is unclear how the removal of the dyes will affect the company's business, since consumers can perceive the products as healthier, but can also be attracted less by blunt colors.

The decision follows the pressure of the US Food and Drug Administration and the Department of Health and Human Services under the direction of Secretary Robert F. Kennedy Jr., so that the food industry withdraws artificial dyes as part of a larger so-called so-called platform America Healthy Health Making America.

The FDA announced a plan in April to rule out the use of synthetic dyes from a petroleum basis until the end of next year and replace it with natural alternatives. In addition to the previously banned red No. 3, other dyes that are removed were red dye 40, Yellow Dye 5, Yellow Dye 6, Blue Dye 1, Blue Dye 2 and Green Dye 2, said the FDA commissioner Marty Makary at that time.

At the time, Kennedy said that the FDA and the food industry have an “understanding”, no formal agreement to remove artificial dyes. The secretary for health and human services discussed during a meeting in March with top managers from companies such as Kraft Heinz. Pepsico North America, General MillsPresent WK KelloggPresent Tyson FoodsPresent JM Smucker And the Consumer Brands Association, the best trading group in the industry.

A spokesman for Kraft Heinz said on Tuesday that the company was looking forward to working with the administration “to offer all high -quality, affordable and healthy food for everyone”.

Dynamics against food dyes have built up for years. In January, before President Donald Trump and Kennedy assumed his office, the FDA announced a ban on the use of red No. 3 -Due for food and recorded drugs. The dye gives many sweets and grain their bright red color, but is also known to be caused by cancer in laboratory animals. The FDA allowed Red No. 3 for years by food manufacturers, although the state of California had already banned the dye in 2023.

In the publication on Tuesday, Kraft Heinz said that there have been more than 1,000 recipe changes in the past five years to improve product nutrition.

“The vast majority of our products use natural or no colors, and we were on a trip to reduce the use of FD & C colors in the rest of our portfolio,” said Navio. “Above all, we focus on providing nutritious, affordable and great -tasting foods to the Americans, and this is a privilege that we do not take easily.”

Do not miss these findings from CNBC Pro

Sword Health, a startup that focuses on dealing with people with digital services, is expanding to mental health and has increased additional capital to promote its growth.

The 10-year-old company introduces Mind, which uses a combination of artificial intelligence, hardware and experts for human health to treat patients with mild depression and fear. Sword said Mind will help users access care if they need them and not during sporadic, hourly appointments.

“It is really a breakthrough with regard to the fight against mental health, and this is only possible because we have AI,” Sword -CEO Virgílio Bento told CNBC in an interview.

Also on Tuesday, Sword announced a round of funding in General Catalyst of $ 40 million in a deal that evaluates the company with $ 4 billion. The new money will support SWORD's efforts to grow through acquisitions and its global expansion and AI model development, the company said.

The round included the participation of Khosla Ventures, Comcast Companies and other companies. According to PitchBook, Sword had collected a total of more than 450 million US dollars in September.

Funding areas as a market for digital health shows signs of recovery after a difficult expansion of imitation when inflation rising interest rates and a return on personal activities led to a dramatic retreat in the industry.

Early this month, Omada HealthThe virtual care programs offer to support patients with chronic diseases such as diabetes and high blood pressure, has held its NASDAQ debut, even though the share is traded under the stock market course of the IPO. Weeks earlier, provider of digital physiotherapy Health hinge Beat the New York stock exchange. The stocks act a few dollars over their offer price.

Sword, which was founded in Portugal and is now based in New York, offers tools for digital physiotherapy, health and movement of the pelvis and movement to help patients cope with pain from home and avoid other treatments such as opioids and operations. Patients can register for sword if they are supported by their employer or their health plan.

Mind users receive a wrist-compatible than “M band” that can measure environmental and physiological signals such as heart rate, sleep and lighting in the area of ​​a user. Mind also includes access to a AI carer and human health professionals for mental health who can provide services such as traditional talcage therapy.

Bento said that a person was always involved in the care of a patient and that AI does not make clinical decisions.

For example, if a patient has an anxiety, the SWORD KI will recognize this and ask a clinic to approved physical activity for later on that day to help with recovery. The clinician would either agree with the physical activity that the AI ​​proposed, or overridden it and suggested something else.

“You have a problem with anxiety today, and the way you can talk about it is to talk about it in a week? It just doesn't work,” said Bento. “Mental health should always be switched on where you now have a problem and you can help immediately at the moment.”

Bento said sword had some customers who were on a waiting list for spirit, and the startup tested the offer with some of its design partners. He said early users had approved the personalized approach and the convenience of Mind.

“We believe that it is really the future of how mental health will be delivered by us and other companies in the future,” said Bento. “AI plays a very important role, but the use of AI – and I think that is very important – must be used very intelligently.”

Disclosure: Comcast, parents of Comcast Ventures, is the owner of NBCUNIERSAL, parent company of CNBC.

Wache: billionaire investor Vinod Khosla about the investments of sword health, opportunities in AI and AI competition

Biostatistician and epidemiologist Martin Kulldorff, MD, PhD, and Dr. Mina Zadeh, Acip Executive Secretary, CDC, Look on As People Present Their Information to Members of the Advisory Committee on Immunization Practices, As The Us Centers for Disease Control and Prevention's (CDC) Advisory Panel for Vaccines Convenes, in Atlanta, Us June 25, 2025.

Megan Varner | Reuters

A version of this article was first published in CNBCS Healthy Return's newsletter, in which the latest health news leads directly to their inbox. Subscribe here to get future expenses.

A revised government group of vaccine advisors with newly appointed immunization skeptics voted against a mercury-containing shot ingredient that the anti-vaccination movement has long targeted.

The group, which was referred to as the advisory committee for immunization practices or ACIP, voted on Thursday with the recommendation of an annual single dose flu for the Americans and against influenza recordings that contained thimerosal no reference to damage from this preservative. It was the first acip meeting since the secretary for health and human services, Robert F. Kennedy Jr.

The centers for the control and prevention of diseases still have to unsubscribe. If the agency is the case, this would affect about 4% to 5% of the US flu vaccine supply.

The rest of the nation's flu photos was free of Thimerosal, according to the CDC data last season. But when it comes to vaccinating an entire country, said “small percentages,” said Dr. Sean O'Leary, an expert for infectious diseases at the American Academy of Pediatrics, to reporters last week.

If the few thimerosal flu shots were removed from the market,

“This would inevitably lead to fewer people to be vaccinated at least for a short time, possibly for a long time and then more hospital stays and deaths,” said O'Leary.

The recommendation also increases long -term, unfounded fears that the substance can lead to developmental disorders such as autism. Kennedy's skepticism of vaccine concluded the circle with the coordination of the body: A decade before he entered his current role, he published a book that demanded the removal of Thimerosal from Schüussen and linked it to developmental disorders.

“A very common topic of conversation against accycine is in Thimmerosal. So this is a very clear strategy to sow distrust of vaccines,” said O'Leary.

Susana Sanchez, a nurse, manages a flu vaccination to Loisy Barrera in a CVS pharmacy and in a minute clinic on September 10, 2021 in Miami, Florida.

Joe Raedle | Getty pictures

Here is why thimerosal is important. It has often been used as a preservative for decades to prevent the growth of harmful bacteria in several drugs and vaccines with several doses. More than 40 studies on many decades have not found a connection between thimerosal and developmental delays.

However, the use in approved vaccines has dropped sharply because the manufacturers have shifted to dose packaging for their recordings, which requires no preservatives. The Food and Drug Administration asked the manufacturers about 25 years ago to remove the substance from the vaccine in childhood from a lot of caution, not due to damage according to the CDC.

“The thought was that Merkur is a scary word, and just let it out, just let us do this into a non-identified one,” said O'Learly. He added that “many studies have shown that it is completely safe, have no neurological developmental disorders or other adverse effects”.

Some multi-dose forms of flu vaccine for adults still contain thimerosal, including Sanofis fluzone and two shots from the biotech company CSL SEQIRUS.

A member of the committee, Dr. Cody Meissner, Professor of Pediatrics at Dartmouth Geisel School of Medicine, said that he was concerned that the disposal of the use of multidosis vials could increase the costs for vaccination and restrict access for some groups. He also commented on concerns about the message that would send the recommendation to other countries in which the use of multi-dose of fluance vaccines is more common.

“This could restrict the availability of the Influenza vaccine for some people,” he said during the meeting after he had voted against the restriction of the flu in the Thimerosal.

Before the votes of the meeting, Lyn Redwood, a nurse who dealt with anti-access organizations was presented in Thimerosal in flu vaccine. Redwood is one of the “Mercury Mothers” who urged Kennedy to deal with Mercury and Children's Health. She also worked for years as President of the Child Health Defense, the anti-Accacine organization founded by Kennedy.

Feel free to send Annikakim.constantino@nbcuni.com tips, suggestions, ideas and data to Annika.

Latest in the healthcare system Tech: Arcadia, which was acquired by the private equity company Nordic Capital

The health data platform Arcadia was taken over by the private equity company Nordic Capital, the companies announced on Tuesday.

Arcadia puts health data into predictive knowledge that payers and providers can use to improve the care of patients, reduce costs and increase sales. The company described the deal with Nordic Capital as a “strategic partnership”, in which the company becomes Arcadia according to a publication of the “majority owners”.

Michael Meucci, CEO of Arcadia, said the cooperation with Nordic Capital would enable Arcadia to further improve his customer experience, to expand his skills for artificial intelligence, to explore new M&A opportunities and to improve growth in its core segments, including value-based care.

“It is very validating,” Meucci told CNBC in an interview. “It must be validated that there are institutional investors with large chapters that are also committed to changing us (US?) Health care and global health care as well.”

Arcadia and Nordic Capital have not disclosed the conditions of the acquisition. The deal is expected to be completed in the second half of the year, although it is still subject to regulatory permits.

Meucci said he knew the Nordic capital team for a few years and the company has observed Arcadia's progress as a company. Arcadia is profitable and carried out a successful acquisition last year. Meucci said these milestones made Nordic Capital confidently that the company was ready for the next growth phase.

Arcadia recently collected outside of the financing in 2023 when there were $ 125 million in financing Vista credit partners. The Nordic Capital acquisition serves as an exit of former investors, said Arcadia.

“This partnership corresponds seamlessly with Nordic Capital's investment strategy, and Nordic Capital is pleased to support Arcadia in his next phase of growth,” said Daniel Berglund, partner and co-manager of health care at Nordic Capital.

TripleTree served as a financial advisor for Nordic Capital for the transaction, and Lazard advised Arcadia.

“This is just a further reinforcement of our mission that we have to change the costs of health care,” said Meucci.

Read the complete publication here.

Feel free to send tips, suggestions, story ideas and data to Ashley at Ashley.capoot@nbcuni.com.